Opinion|Videos|January 13, 2025
Patient Case: AE Management in Practice With 1L IV Amivantamab
Panelists discuss practical insights and learning opportunities through interactive examination of a patient case.
Advertisement
Video content above is prompted by the following:
- Please present slides with patient case details and moderate brief discussion.
Advertisement
Related to this article
Erik Bengtsen, MD, of Memorial Sloan Kettering Cancer Center, discusses psilocybin research, demoralization, and psychopharmacology in oncology care.
Ramy Sedhom, MD, of Penn Medicine Princeton Health discusses blending palliative care with psycho-oncology to treat patient distress in oncology care.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.
For Gynecologic Cancer Awareness Month, Dr. Eleonora Teplinsky outlines emerging treatment toxicities, patient advocacy, and health equity.
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
Gigi Jameel, APRN, discusses supportive care interventions, ADT toxicity management, and team collaboration in prostate cancer care.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Palliative and Psycho-Oncology Care: Dr. Ramy Sedhom on Patient Distress Signs
2
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
3
Psycho-Oncology Care: Dr. Erik Bengtsen on Psilocybin & Patient Distress
4
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
5